SUTRO BIOPHARMA, INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
SUTRO BIOPHARMA, INC. (STRO) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of -$936.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-25.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2024-03-25
- 2023-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net -$936.00K.
- 2022-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net -$646.00K.
- 2021-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net -$113.00K.
- 2020-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $455.00K.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2023-12-31 | -$936.00K 10-K · filed 2024-03-25 |
| 2022-12-31 | -$646.00K 10-K · filed 2024-03-25 |
| 2021-12-31 | -$113.00K 10-K · filed 2023-03-30 |
| 2020-12-31 | $455.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |